Ignite Creation Date:
2025-12-25 @ 1:32 AM
Ignite Modification Date:
2026-03-03 @ 9:16 PM
Study NCT ID:
NCT02279394
Status:
COMPLETED
Last Update Posted:
2023-06-09
First Post:
2014-09-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Sponsor:
Dana-Farber Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-12-11
Start Date Type:
ACTUAL
Primary Completion Date:
2018-12-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-01-26
Completion Date Type:
ACTUAL
First Submit Date:
2014-09-26
First Submit QC Date:
None
Study First Post Date:
2014-10-31
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-09-15
Results First Submit QC Date:
None
Results First Post Date:
2023-06-09
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-05-15
Last Update Post Date:
2023-06-09
Last Update Post Date Type:
ACTUAL